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Introduction 
Ashy dermatosis is a type of acquired macular 
hyperpigmentation characterized by asymptomatic, 
symmetrically-distributed, gray macules of unknown 
pathophysiology [1]. Although most commonly 
found in the Central and South American population, 
ashy dermatosis demonstrates a worldwide 
prevalence [2-5]. Ashy dermatosis can appear at any 
season of the year in patients of any age group or 
gender [2, 6]. Although primarily a cosmetic issue, its 
prevalence and prominent appearance in dark 
skinned individuals can be very troubling for 
patients. Therefore, this rare, dermatologic condition 
warrants increased clinician awareness. 
Ashy dermatosis has been commonly referred to as 
erythema dyschromicum perstans and some authors 
feel that it is synonymous with lichen planus 
pigmentosus. Unfortunately, the plethora of names 
from different countries for this presentation makes 
it difficult to make meaningful advances in our 
understanding of this disease. This ashy dermatosis 
review serves as a single source for clinicians to stay 
up-to-date regarding the history, clinical 
presentation, histologic features, pathogenesis, 
differential diagnosis, management, and outcomes. 
A literature search was performed using MEDLINE 
(Ovid SP and PubMed). Search terms used in this 
database were as follows: “ashy dermatosis,” 
“erythema dyschromicum perstans,” OR “lichen 
planus pigmentosus.” The search date range was 
selected from January 1, 1970 through December 31, 
2018. 
History 
Ashy dermatosis was first described in 1957 by 
Ramirez in El Salvador as “Los Cenicientos,” or the 
ashen ones, for its asymptomatic, ash-colored, 
macular hyperpigmentation [7]. This clinical 
presentation was later described in 1961 as 
erythema dyschronicum perstans by Convit in 
Caracas [8]. The relationship between ashy 
Abstract 
Ashy dermatosis is characterized by asymptomatic, 
symmetrically-distributed, gray-colored macules 
located on the trunk, neck, face, and upper 
extremities. The condition occurs most commonly in 
patients with Fitzpatrick phototype III-V skin. The 
etiology is unknown, but drug ingestion, infection, 
and genetic factors have been suggested to elicit 
ashy dermatosis. No gold standard treatments have 
been established yet. The most successful treatment 
to date has been clofazimine, although topical 
tacrolimus, oral dapsone, narrowband ultraviolet 
light B phototherapy, and isotretinoin have shown 
treatment success. Ashy dermatosis is primarily a 
cosmetic concern, but can be a very distressing 
condition, especially for dark skinned individuals. 
Therefore, an increase in clinician awareness and 
more studies are needed to further understand the 
etiology and treatment options for this disease. This 
review serves as a single source for clinicians to stay 
up-to-date regarding the history, clinical 
presentation, histology, pathogenesis, differential 
diagnosis, and management options for ashy 
dermatosis. It also suggests an alternative name that 
more appropriately encompasses the clinical and 
histopathologic features, while acknowledging our 
lack of understanding of its etiology: macular 
hyperpigmentation of indeterminate etiology. 
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dermatosis and erythema dyschromicum perstans is 
still debated, with many considering the two to be 
identical in the literature. Most recently, Zaynoun 
proposed the classification of erythema 
dyschromicum perstans to display lesion 
characteristics similar to ashy dermatosis, but that 
erythema dyschromicum perstans also includes 
lesions that currently present with or have had 
erythematous borders [9]. Other labels that may 
have been used or confused with ashy dermatosis in 
the past include Riehl’s melanosis, Cinderella 
dermatosis, erythema chronicum figuratum 
melanodermicum, and lichen planus pigmentosus 
[10, 11]. 
Clinical Presentation 
Ashy dermatosis presents as slowly progressive, 
gray-colored, macular hyperpigmentation that is 
deeper than epidermal pigmentary disorders 
(Figure 1). It occurs most often in patients with 
Fitzpatrick skin type III-V phototypes [4]. Lesions can 
be symmetrically distributed over the trunk, neck, 
upper extremities, and face [4, 12]. Ashy dermatosis 
lesions typically start as small, 3mm size macules but 
can slowly coalesce to form large patches over the 
course of several weeks (Figure 2). Lesions typically 
spare the palms, soles, nails, and mucous 
membranes. However, reports exist of lesions 
occurring in the oral mucosa [13]. It is typically 
asymptomatic. Atypical lesions can be accompanied 
by peripheral erythematous borders, pruritus, or 
scaling [4, 14]. The lesions can become confluent and 
involve almost the whole skin, with no preference for 
photoexposed areas [15]. 
Dermoscopy can assist in differentiating ashy 
dermatosis from other similar dermatoses by 
displaying gray-bluish small dots over a bluish 
background, corresponding to melanophages or 
melanin deposits in the deeper dermis [16]. 
Histology 
Characteristic histology features, although not 
pathognomonic, depend on the lesion phase. Active 
or early lesions can display basal vacuolar 
degeneration, papillary dermis edema, or 
perivascular lymphocytic infiltration [4]. Inactive or 
late lesions demonstrate pigment incontinence in 
the dermis and melanophages (Figure 3). As lesions 
progress, inflammatory infiltrate diminishes. 
Perivascular or subepidermal fibrosis, pigmentary 
alteration, or lichenoid infiltration can also be seen 
[17, 18]. The lichenoid changes could be restricted to 
the periphery of the lesion and can be missed if not 
included in the biopsy [2]. 
Direct immunofluorescence showing colloid IgM 
suggests a diagnosis of ashy dermatosis [18]. The 
presence of cutaneous lymphocyte antigen positive 
cells in the basement membrane zone suggests that 
ashy dermatosis can be a response to antigenic 
stimulation [19]. There is excess expression of 
intercellular adhesion molecule 1 and HLA-DR in the 
 
Figure 1. Symmetric hyperpigmented oval brown patches on 
the neck and upper trunk of a 51-year-old Hispanic female.
\ 
Figure 2. Hyperpigmented macules that have coalesced into a 
large patch in the axilla of a patient. Reprinted with permission 
from www.dermnetnz.org. 
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keratinocyte basal cell layer of ashy dermatosis 
lesions [20]. Further, individuals with ashy 
dermatosis have an abnormal expression of CD36 
(thrombospondin receptor) not expressed by normal 
skin, in the strata spinosum and granulosum [20]. 
Etiology/Pathogenesis 
The etiology of ashy dermatosis is unknown. There 
are no lab tests or radiographic studies that are 
pathognomonic. Many predisposing factors have 
been cited including: infections such as intestinal 
parasitism (control of which produced remission of 
active skin lesions), [21], enterovirus [22], HIV 
seroconversion [23], and chronic hepatitis C [24]; 
environmental insults such as ingestion of 
ammonium nitrate [25], orally administered X-ray 
contrast media [26], ethambutol [27], fluoxetine [28], 
chlorothalonil [29], and omeprazole [30]; and genetic 
factors such as the HLA-DR4 allele [12]. Similar 
macules have been described in individuals with a 
cobalt allergy [31]. 
Differential Diagnosis 
Controversy exists whether ashy dermatosis and 
lichen planus pigmentosus are separate clinical 
diagnoses. There are some clinical differences 
between ashy dermatosis and lichen planus 
pigmentosus such as the presence of pruritus and 
burning sensation. Lichen planus pigmentosus has a 
more localized distribution with facial involvement, 
compared with the typical truncal involvement in 
ashy dermatosis [32]. Palmoplantar involvement can 
be found in both conditions [33]. In addition, lichen 
planus pigmentosus exhibits a waxing and waning 
course as compared to the stable clinical course seen 
in ashy dermatosis [32]. 
Dermoscopic examination of lichen planus 
pigmentosus can reveal a diffuse brown background 
with pseudo-networks and gray globules and 
blotches [34]. In vivo reflectance confocal 
microscopy consistently shows blurring of the 
papillary dermis with dense and highly refractive 
lymphocytes in the superficial dermis [35]. 
Histologically, ashy dermatosis lacks a well-defined 
histopathological profile. Furthermore, its tendency 
to exhibit a lichenoid reaction can be very similar to 
other inflammatory disorders. Because ashy 
dermatosis and lichen planus pigmentosus both 
display similar histologic features, differentiating 
between the two is challenging [36]. 
Macules can present along the lines of Blaschko and 
mimic pityriasis rosea [37]. Ashy dermatosis macules 
typically persist as compared to the spontaneous 
resolution seen in pityriasis rosea. However, in 
individuals with a history of pityriasis rosea, it is 
reasonable to conclude that the gray macules can be 
classified as a postinflammatory hyperpigmentation 
related to pityriasis rosea. 
Idiopathic eruptive macular pigmentation may 
resemble ashy dermatosis owing to the clinical 
features of asymptomatic, nonconfluent brown 
macules located on the trunk, neck, and proximal 
extremities. Histopathologic findings can include 
 
Figure 3. Low (top, H&E, 20×) and high (bottom, H&E, 100×) 
power histologic images showing epidermal atrophy, focal 
vacuolar alteration of basal cells, perivascular lymphoid cell 
infiltrate, and numerous melanophages. 
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hyperpigmentation of the epidermal basal layer, 
prominent dermal melanophages, or lichenoid 
inflammatory infiltrate with normal mast cell counts 
[38]. Spontaneous resolution is expected within 
several months or years, which is similar to ashy 
dermatosis in children, but differs from ashy 
dermatosis in adults. However, the pigmented 
macules in idiopathic eruptive macular 
hyperpigmentation are smaller in size (ranging from 
5 to 25mm) as compared to the larger macules (3mm 
or larger) and patches seen in ashy dermatosis [39]. 
Post-inflammatory hyperpigmentation differs in the 
history, clinical presentation, dermoscopy features, 
and histology findings. A fixed drug eruption may 
appear similar to ashy dermatosis, but differs in that 
a fixed drug eruption is more circular in shape and 
brown in color as compared to the gray color in ashy 
dermatosis. 
Management and Outcomes 
It is important to obtain a thorough medical history 
with an emphasis on medication or drug ingestion. 
Physical examination should include an oral and 
genital examination. Punch biopsy may be indicated 
to exclude other causes of hyperpigmentation, 
particularly lichen planus. 
The clinical course of ashy dermatosis is different 
between children and adults. In children, ashy 
dermatosis typically resolves in two to three years [2, 
40]. Although spontaneous resolution in adults has 
been reported, ashy dermatosis lesions in adults 
usually persist and have a chronic course [41]. 
No gold standard exists for treatment of ashy 
dermatosis. Chang et al. [4] administered a variety of 
topical (steroids, hydroquinone, calcineurin 
inhibitors, and tretinoin) and systemic treatments 
(dapsone, minocycline, tranexamic acid, clofazimine, 
pentoxifylline, and macrolides). However, most cases 
(55%) did not respond or worsened.  
Treatment with clofazimine is the most commonly 
used medication despite its lack of curative effect [3]. 
One clinical trial achieved an excellent to good 
response in seven of eight patients treated with 
clofazimine. Histologic analysis revealed that, after 
clofazimine therapy, expression of intercellular 
adhesion molecule 1, HLA-DR, and mononuclear cell 
infiltrate disappeared [20]. In addition, clofazimine 
masks the lesions by causing a homogeneous 
coloration of the skin, rendering a cosmetic effect. 
Other potential therapeutic options, albeit with 
variable efficacy and recurrence rates, include topical 
tacrolimus 0.1% [42], oral dapsone [43], isotretinoin 
[44], and narrowband ultraviolet light B 
phototherapy [45]. 
Light therapy is a promising treatment modality. 
Although non-ablative fractional laser treatment 
alone was ineffective in treating ashy dermatosis, 
one recent report highlighted >75% improvement 
with maintenance after eight months after treatment 
with non-ablative fractional laser in combination 
with topical tacrolimus 0.1% ointment [46]. However, 
laser-induced postinflammatory hyperpigmentation 
can occur, further exacerbating the cosmetic 
concerns in ashy dermatosis [47]. 
Ashy dermatosis can often be misdiagnosed or 
confused with lichen planus pigmentosus given their 
overlapping features. However, successfully 
reported treatments are largely the same. Topical 
tacrolimus for 8 weeks renders moderate treatment 
success in lichen planus pigmentosus [48]. Q-
switched Nd-YAG laser in combination with topical 
tacrolimus is also effective in treating stable lichen 
planus pigmentosus [49]. 
Time for a Name Reappraisal 
The name ashy dermatosis has been upheld since it 
was conceived in 1957 by Ramirez in El Salvador. 
Although the name is partially descriptive of its 
appearance, there does not appear to be enough 
evidence to distinguish it from lichen planus 
pigmentosus or erythema dyschromicum perstans. 
The main differentiating points between the 
aforementioned diagnoses are too imperceptible 
(erythematous ring surrounding a macule) or too 
variable (pruritus, symmetry, histopathology). 
Traditionally, the erythematous halo surrounding a 
macule has been the differentiating factor that 
suggests a diagnosis of ashy dermatosis over lichen 
planus pigmentosus. However, in one 
clinicopathologic study involving 31 cases of ashy 
dermatosis and lichen planus pigmentosus, this 
critical feature was present in only 40% of ashy 
dermatosis diagnoses [36]. Furthermore, there were  
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insignificant differences in the histologic features 
between the two. Chandran et al. [1] recently 
proposed that patients with the clinical features of 
lichen planus concurrent with the gray macules 
should be classified as having lichen planus 
pigmentosus. Though helpful if present, only 9% of 
patients presenting with the lichen planus 
pigmentosus also observed lichen planus, limiting its 
utility in classifying lichen planus pigmentosus over 
ashy dermatosis [36]. 
It is difficult to advance our understanding of this 
disease when clinicians from different countries have 
different names for this presentation. For now, we 
propose the nomenclature “macular hyperpig-
mentation of indeterminate etiology.” We believe 
that this name properly incorporates the clinical and 
histopathologic characteristics, while 
acknowledging our lack of understanding of the 
pathogenesis. 
Conclusion 
Ashy dermatosis is characterized by asymptomatic, 
symmetrically-distributed, gray-colored macules 
located on the trunk, neck, face, and upper 
extremities. Although primarily a cosmetic concern, 
ashy dermatosis can be a very distressing 
dermatologic condition, especially in patients with 
Fitzpatrick phototype III-V skin. Therefore, an 
increase in clinician awareness and additional 
studies are needed to further understand the 
pathogenesis and successful treatment options for 
this disease. We propose that “macular 
hyperpigmentation of indeterminate etiology” 
replace ashy dermatosis as it a more accurate and 
more appropriate name for this condition. 
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